SEC Form SC 13G/A filed by Surface Oncology Inc. (Amendment)

2/9/22 10:01:24 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $SURF alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 1 SURFACE ONCOLOGY INC COMMON STOCK Cusip #86877M209 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #86877M209 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,163,556 Item 6: 0 Item 7: 1,729,801 Item 8: 0 Item 9: 1,729,801 Item 11: 3.749% Item 12: HC Cusip #86877M209 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 1,729,801 Item 8: 0 Item 9: 1,729,801 Item 11: 3.749% Item 12: IN Item 1(a). Name of Issuer: SURFACE ONCOLOGY INC Item 1(b). Address of Issuer's Principal Executive Offices: 50 HAMPSHIRE STREET, 8TH FLOOR CAMBRIDGE, MA 02139 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 86877M209 Item 3. Not Applicable Item 4. Ownership (a) Amount Beneficially Owned: 1,729,801 (b) Percent of Class: 3.749% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 1,163,556 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 1,729,801 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of SURFACE ONCOLOGY INC. No one other person's interest in the COMMON STOCK of SURFACE ONCOLOGY INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2022 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Crosby Advisors LLC N/A Fidelity Management & Research Company LLC IA IMPRESA MANAGEMENT LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2022, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of SURFACE ONCOLOGY INC at December 31, 2021. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $SURF alert in real time by email

SEC Form SC 13G/A filed by Surface Oncology Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for
$SURF

$SURF
Press Releases

Fastest customizable press release news feed in the world

Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote "FOR" the Proposed Merger with Coherus BioSciences

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023

Lifshitz Law PLLC Announces Investigations of SURF, NETI, NEX, and PTEN

$SURF
Financials

Live finance-specific insights

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023

Coherus to Acquire Surface Oncology

Coherus to Acquire Surface Oncology

$SURF
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

BTIG Research initiated coverage on Surface Oncology with a new price target

$SURF
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Adams Chandra returned 23,884 shares to the company, closing all direct ownership in the company

SEC Form 4: Sigal Charles Elliott returned 45,453 shares to the company

SEC Form 4: Palombella Vito J. returned 87,212 shares to the company, closing all direct ownership in the company

$SURF
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Surface Oncology Inc.